Evercore ISI initiated coverage of vTv Therapeutics (VTVT) with an Outperform rating and $44 price target Cadisegliatin, a potential first-in-class, once-daily, oral, liver-selective glucokinase activator being developed as an adjunct to insulin in type 1 diabetes, has “looked comparatively well-behaved to date,” the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTVT:
- vTv Therapeutics price target raised to $55 from $35 at Alliance Global
- Buy Rating on vTv Therapeutics Underpinned by Late-Stage T1D Catalyst, Strengthened Balance Sheet, and Diversified Partnership-Driven Upside
- vTv Therapeutics Highlights Cadisegliatin Phase 3 and Cash Runway
- vTv Therapeutics reports Q4 EPS (58c), consensus ($1.09)
- vTv Therapeutics Highlights Cadisegliatin Progress and Financial Strength